EP1515748A4 - Anti-estrogen and immune modulator combinations for treating breast cancer - Google Patents
Anti-estrogen and immune modulator combinations for treating breast cancerInfo
- Publication number
- EP1515748A4 EP1515748A4 EP02793936A EP02793936A EP1515748A4 EP 1515748 A4 EP1515748 A4 EP 1515748A4 EP 02793936 A EP02793936 A EP 02793936A EP 02793936 A EP02793936 A EP 02793936A EP 1515748 A4 EP1515748 A4 EP 1515748A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- estrogen
- breast cancer
- immune modulator
- treating breast
- modulator combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33280101P | 2001-11-14 | 2001-11-14 | |
US332801P | 2001-11-14 | ||
PCT/US2002/036633 WO2003041654A2 (en) | 2001-11-14 | 2002-11-13 | Anti-estrogen and immune modulator combinations for treating breast cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1515748A2 EP1515748A2 (en) | 2005-03-23 |
EP1515748A4 true EP1515748A4 (en) | 2006-04-12 |
Family
ID=23299909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02793936A Withdrawn EP1515748A4 (en) | 2001-11-14 | 2002-11-13 | Anti-estrogen and immune modulator combinations for treating breast cancer |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1515748A4 (en) |
AU (1) | AU2002359401A1 (en) |
WO (1) | WO2003041654A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MD20140054A2 (en) | 2011-12-16 | 2014-10-31 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859585A (en) * | 1986-04-17 | 1989-08-22 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of estrogens |
US4919937A (en) * | 1984-01-20 | 1990-04-24 | Mauvais Jarvis Pierre | Percutaneous administration of tamoxifen |
EP1366366A2 (en) * | 2000-05-10 | 2003-12-03 | David A. Sirbasku | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6261787B1 (en) * | 1996-06-03 | 2001-07-17 | Case Western Reserve University | Bifunctional molecules for delivery of therapeutics |
-
2002
- 2002-11-13 EP EP02793936A patent/EP1515748A4/en not_active Withdrawn
- 2002-11-13 WO PCT/US2002/036633 patent/WO2003041654A2/en not_active Application Discontinuation
- 2002-11-13 AU AU2002359401A patent/AU2002359401A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4919937A (en) * | 1984-01-20 | 1990-04-24 | Mauvais Jarvis Pierre | Percutaneous administration of tamoxifen |
US4859585A (en) * | 1986-04-17 | 1989-08-22 | Trustees Of Tufts College | In-vitro methods for identifying compositions which are agonists and antagonists of estrogens |
EP1366366A2 (en) * | 2000-05-10 | 2003-12-03 | David A. Sirbasku | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
Non-Patent Citations (5)
Title |
---|
BRODIE A ET AL: "Aromatase inhibitors and their antitumor effects in model systems.", ENDOCRINE-RELATED CANCER. JUN 1999, vol. 6, no. 2, June 1999 (1999-06-01), pages 205 - 210, XP002367011, ISSN: 1351-0088 * |
MCCORMICK DAVID L ET AL: "Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland", CANCER RESEARCH, vol. 56, no. 8, 1996, pages 1724 - 1726, XP008057031, ISSN: 0008-5472 * |
ROSSO R ET AL: "ADJUVANT SYSTEMIC TREATMENT OF RESECTABLE BREAST CANCER ELEVEN YEARS RESULTS OF A MONOINSTITUTIONAL CHEMO-HORMONE-IMMUNOTHERAPY TRIAL", ANTICANCER RESEARCH, vol. 9, no. 4, 1989, pages 1153 - 1156, XP008057015, ISSN: 0250-7005 * |
SAVAGE P ET AL: "A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily", BRITISH JOURNAL OF CANCER, vol. 74, no. 9, 1996, pages 1482 - 1486, XP002073161, ISSN: 0007-0920 * |
SAWAI K ET AL: "CHEMO-ENDOCRINE-IMMUNOTHERAPY WITH ADRIAMYCIN TAMOXIFEN AND OK-432 PICIBANIL FOR ADVANCED BREAST CANCER", JOURNAL OF JAPAN SOCIETY FOR CANCER THERAPY, vol. 19, no. 6, 1984, pages 1315 - 1320, XP008057016, ISSN: 0021-4671 * |
Also Published As
Publication number | Publication date |
---|---|
EP1515748A2 (en) | 2005-03-23 |
WO2003041654A2 (en) | 2003-05-22 |
WO2003041654A3 (en) | 2005-01-06 |
AU2002359401A1 (en) | 2003-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL251270A0 (en) | Cancer treatment | |
EP1399460A4 (en) | Breast cancer-associated genes and uses thereof | |
SI1176964T1 (en) | Uses of et743 for treating cancer | |
EP1320376A4 (en) | Treatment of prostate cancer | |
MXPA03008582A (en) | Agents and methods for treatment of cancer. | |
EP1694364A4 (en) | System for treating and preventing breast cancer | |
EP1416960A4 (en) | Vegfr-1 antibodies to treat breast cancer | |
AU2002351374A8 (en) | Antibodies to treat cancer | |
GB0005257D0 (en) | Breast cancer hormonal therapy | |
EP1401377A4 (en) | Methods for treating cancer | |
IL161762A0 (en) | Estradiol inhibiting agents in breast cancer | |
EP1401494A4 (en) | Tumor therapy | |
EP1515748A4 (en) | Anti-estrogen and immune modulator combinations for treating breast cancer | |
GB0026015D0 (en) | Cancer treatment | |
IL149281A0 (en) | Treatment of cancer | |
AU2002366364A8 (en) | E2f and cancer therapy | |
EP1463511A4 (en) | Combination cancer therapy | |
GB0223325D0 (en) | Treating cancer | |
AU2002360454A8 (en) | Methods and compositions for treating cancer | |
GB0027780D0 (en) | Treating cancer | |
GB0007254D0 (en) | Treating cancer | |
GB9911302D0 (en) | Treating cancer | |
GB9908176D0 (en) | Cancer treatment | |
GB0105244D0 (en) | Cancer treatment methods and compositions | |
GB2383538B (en) | Cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIRBASKU, DAVID A. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SIRBASKU, DAVID A. |
|
17P | Request for examination filed |
Effective date: 20050615 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060224 |
|
17Q | First examination report despatched |
Effective date: 20070214 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIGNE BIOPHARMA INC. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SIRBASKU, DAVID A. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SIGNE BIOPHARMA INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080710 |